Lupus & antiphospholipid syndrome
Real-world treatment patterns and outcomes in moderate-to-severe SLE: findings from the Spanish SLE Prospective Observational Cohort Study (SPOCS) cohort
Authors' conclusion
In Spanish clinical practice, sustained remission and low disease activity state remain uncommon in moderate-to-severe SLE. Nearly half had organ damage at baseline, with continued accrual and impaired HRQoL.
Study context
- Population
- Adults with active SLE and moderate-to-severe disease activity, 18 Spanish sites (2017–2019), followed every 6 months for up to 3 years
- Participants
- 99 adults
- Outcome
- Disease activity, remission, LLDAS and organ damage
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
- Baseline SLEDAI-2K, median (IQR)
- 8 (7-12)
- Organ damage at baseline
- 45%
- Baseline SDI, mean (SD)
- 1.1 (1.6)
- Remission at 6 months and at 24 months
- 13%
- Sustained remission
- 9%
- Lupus Low Disease Activity State (LLDAS) at 6 months
- 24%
- LLDAS thereafter
- ≤22%
- LLDAS maintained for ≥70% of follow-up
- 8%
- Median SLEDAI-2K at 6 months
- 4
- New or worsening organ damage at 12, 24 and 36 months
- 11%, 8% and 12%
- Mean SDI (SD) by 36 months
- 1.8 (2.0)
Observational data: associations, not effects.
Further findings
Health-related quality of life (HRQoL)
- Depressive symptoms (PHQ-8 ≥5)
- 60%-75%
- Moderate-to-severe depression (PHQ-8 ≥10)
- 35%-50%
- Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) (persistent severe fatigue)
- ≈30
- Mean EQ-5D-5L index
- 0.70-0.75
- Pain/discomfort
- up to 76%
- Anxiety/depression
- up to 66%
Original publication
Real-world treatment patterns and outcomes in moderate-to-severe SLE: findings from the Spanish SPOCS cohort. Lupus Sci Med. Published 16 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →